Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Short-term Investments (2016 - 2025)

Purple Biotech has reported Short-term Investments over the past 7 years, most recently at $431000.0 for Q4 2022.

  • Quarterly Short-term Investments fell 98.81% to $431000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $431000.0 through Dec 2022, down 98.81% year-over-year, with the annual reading at $431000.0 for FY2022, 98.81% down from the prior year.
  • Short-term Investments was $431000.0 for Q4 2022 at Purple Biotech, down from $22.0 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $46.6 million in Q4 2020 and troughed at $10000.0 in Q2 2020.
  • The 5-year median for Short-term Investments is $19.0 million (2022), against an average of $19.9 million.
  • Year-over-year, Short-term Investments crashed 99.8% in 2020 and then skyrocketed 378360.0% in 2021.
  • A 5-year view of Short-term Investments shows it stood at $1.5 million in 2018, then surged by 31.49% to $2.0 million in 2019, then soared by 2227.9% to $46.6 million in 2020, then fell by 22.01% to $36.3 million in 2021, then crashed by 98.81% to $431000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Short-term Investments are $431000.0 (Q4 2022), $22.0 million (Q3 2022), and $22.0 million (Q2 2022).